In this issue:
ASCO supports use of 177Lu-PSMA-617 radioligand therapy
Consensus delineation guidelines for pelvic lymph node radiation therapy
TheraP: 177Lu-PSMA-617 safer than cabazitaxel for mCRPC
TALAPRO-2 finds PFS benefit to talazoparib + enzalutamide in HRR deficient mCRPC
BRCA2-mutated mCRPC particularly susceptible to PARP inhibition
Black men at greater risk for prostate cancer at all PSA levels
Longitudinal plasma AR-CN status a promising biomarker
PBAC recommendations
Upcoming PBAC agenda items
PBS listings
US approves enzalutamide for recurrent high-risk nonmetastatic CSPC
First-in-human trial of a PSMA-targeted alpha emitter in mCRPC
Could artificial intelligence-aided MRI assessment negate the need for biopsy?
Oral relugolix + SBRT for localised prostate cancer
COVID-19 resources
Conferences & Workshop
Please login below to download this issue (PDF)